Current situation of oncology biosimilars in Japan
Lancet Oncol
.
2021 Mar;22(3):e82.
doi: 10.1016/S1470-2045(21)00029-2.
Author
Sumimasa Nagai
1
Affiliation
1
Translational Research Center, The University of Tokyo Hospital, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Electronic address: sunagai-tky@umin.ac.jp.
PMID:
33662290
DOI:
10.1016/S1470-2045(21)00029-2
No abstract available
Publication types
Letter
Comment
MeSH terms
Biosimilar Pharmaceuticals* / adverse effects
Drug Approval
Humans
Japan
Medical Oncology
Policy
Substances
Biosimilar Pharmaceuticals